SCHEMBL2534641

SCHEMBL2534641

[CH2]Oc1cccc(C(C)(C)O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.39
NR1H3 Q13133 2/20 0.39
SOD1 P00441 1/20 0.36
CETP P11597 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
P2RX4 Q99571 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ALOX15 P16050 1/20 0.33
ACHE P22303 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2536566 0.83 CYP3A4 (0.47) SOD1CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL548657 0.83 NR1H2 (0.49) NR1H2NR1H3SOD1CETPCYP3A4
SCHEMBL2534644 0.82 ACHE (0.48) CYP3A4CYP2C9CYP2C19CYP4F2CYP4A11
SCHEMBL548030 0.78 CETP (0.51) NR1H2NR1H3CETPCYP2C9ALDH1A1
SCHEMBL548150 0.78 NR1H2 (0.46) NR1H2NR1H3SOD1CETPCYP3A4
SCHEMBL304190 0.78 ESR1 (0.50) CYP3A4ESR1ESR2ALDH1A1ALOX15
SCHEMBL548388 0.77 NPC1 (0.47) NR1H2NR1H3CETPCYP3A4CYP2C9
SCHEMBL29718811 0.77 NR1H2 (0.37) NR1H2NR1H3SOD1CETPCYP3A4
SCHEMBL28782372 0.77 NR1H2 (0.37) NR1H2NR1H3SOD1CETPCYP3A4
SCHEMBL1546661 0.77 TP53 (0.52) SOD1CYP3A4CYP2C19ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044070-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2011-10-25 US disclosed
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE MSD K.K. (JP) 2010-08-19 US disclosed
US-7595316-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-29 US disclosed
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2006-08-10 US disclosed
EP-1642898-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative HRH3, HRH4, HCRTR2 NR1H2 89/4885NR1H3 82/4885SOD1 3132/4885
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE HRH3, HRH4, HRH2 NR1H2 62/4885NR1H3 69/4885SOD1 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.